Skip to Content
Merck
CN
  • Plasma PolyQ-ATXN3 Levels Associate With Cerebellar Degeneration and Behavioral Abnormalities in a New AAV-Based SCA3 Mouse Model.

Plasma PolyQ-ATXN3 Levels Associate With Cerebellar Degeneration and Behavioral Abnormalities in a New AAV-Based SCA3 Mouse Model.

Frontiers in cell and developmental biology (2022-04-08)
Karen Jansen-West, Tiffany W Todd, Lillian M Daughrity, Mei Yue, Jimei Tong, Yari Carlomagno, Giulia Del Rosso, Aishe Kurti, Caroline Y Jones, Judith A Dunmore, Monica Castanedes-Casey, Dennis W Dickson, Zbigniew K Wszolek, John D Fryer, Leonard Petrucelli, Mercedes Prudencio
ABSTRACT

Spinocerebellar ataxia type 3 (SCA3) is a dominantly inherited cerebellar ataxia caused by the expansion of a polyglutamine (polyQ) repeat in the gene encoding ATXN3. The polyQ expansion induces protein inclusion formation in the neurons of patients and results in neuronal degeneration in the cerebellum and other brain regions. We used adeno-associated virus (AAV) technology to develop a new mouse model of SCA3 that recapitulates several features of the human disease, including locomotor defects, cerebellar-specific neuronal loss, polyQ-expanded ATXN3 inclusions, and TDP-43 pathology. We also found that neurofilament light is elevated in the cerebrospinal fluid (CSF) of the SCA3 animals, and the expanded polyQ-ATXN3 protein can be detected in the plasma. Interestingly, the levels of polyQ-ATXN3 in plasma correlated with measures of cerebellar degeneration and locomotor deficits in 6-month-old SCA3 mice, supporting the hypothesis that this factor could act as a biomarker for SCA3.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Polyglutamines antibody, Mouse monoclonal, ~2 mg/mL, clone 3B5H10, purified from hybridoma cell culture
Sigma-Aldrich
Anti-Polyglutamine-Expansion Diseases Marker Antibody, clone 5TF1-1C2, ascites fluid, clone 5TF1-1C2, Chemicon®
Sigma-Aldrich
Anti-Spinocerebellar Ataxia Type 3 Antibody, clone 1H9, ascites fluid, clone 1H9, Chemicon®